Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19)

키워드

참고문헌 (104)

1. Lu R, "Genomic characterisation and epidemiology of 2019 novel coronavirus : implications for virus origins and receptor binding", Lancet, 395, pp.565~574 (2020)
2. Gorbalenya AE, "Severe acute respiratory syndrome-related coronavirus : the species and its viruses –a statement of the coronavirus study group", BioRxiv, 20200207, pp.937862~ (2020)
3. Sola I, "Continuous and discontinuous RNA synthesis in coronaviruses", Annu. Rev. Virol, 2, pp.265~288 (2015)
4. Fehr AR, "Coronaviruses : an overview of their replication and pathogenesis", Methods Mol. Biol, 1282, pp.1~23 (2015)
5. Fung TS, "Human coronavirus : host-pathogen interaction", Annu. Rev. Microbiol, 73, pp.529~557 (2019)
6. Li W, "Bats are natural reservoirs of SARS-like coronaviruses", Science, 310, pp.676~679 (2005)
7. Corman VM, "Rooting the phylogenetic tree of middle East respiratory syndrome coronavirus by characterization of a conspecific virus from an African bat", J. Virol, 88, pp.11297~11303 (2014)
8. Zhou P, "Apneumonia outbreak as sociated with a new coronavirus of probable bat origin", Nature, 259, pp.270~273 (2020)
9. Ji W, "Cross-species transmission of the newly identified coronavirus 2019-nCoV", J. Med. Virol, 92, pp.433~440 (2020)
10. "Did pangolins spread the China coronavirus to people?"[URL]
11. Liu P, "Viral Metagenomics Revealed Sendai Virus and Coronavirus Infection of Malayan Pangolins (Manis javanica)", Viruses, 11, pp.E979~ (2019)
12. Graham RL, "A decade after SARS : strategies for controlling emerging coronaviruses", Nat. Rev. Microbiol, 11, pp.836~848 (2013)
13. Peiris JS, "Coronavirus as apossblie cause of severe acute respiratory syndrome", Lancet, 361, pp.1319~1325 (2003)
14. Yang X, "Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a singlecentered, retrospective, observational study", Lancet Respir. Med. (2020)
15. Jin-jin Zhang, "Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan, China", Allergy, 75(7), pp.1730~1741 (2020), Wiley[DOI]
16. Wong ACP, "Global epidemiology of bat coronaviruses", Viruses, pp.11~ (2019)
17. Willman M, "A comparative analysis of factors influencing two outbreaks of Middle Eastern respiratory syndrome (MERS) in Saudi Arabia and South Korea", Viruses, 11, pp.E1119~ (2019)
18. Reusken CB, "MERS-CoV infection of alpaca in a region where MERS-CoV is endemic", Emerg. Infect. Dis, 22, pp.1129~1131 (2016)
19. "WHO Novel Coronavirus (2019-nCoV) SITUATION REPORT - 1 21 JANUARY 2020"[URL]
20. "WHO Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19)"[URL]
21. "WHO Coronavirus disease 2019 (COVID-19) Situation Report – 55 (15 Mar 2020)"[URL]
22. "WHO Coronavirus disease 2019 (COVID-19) Situation Report – 26 (15 Feb 2020)"[URL]
23. "KCDC COVID-19 situation reports in South Korea (24 Feb 2020)"[URL]
24. "KCDC COVID-19 situation reports in South Korea (18 Feb 2020)"[URL]
25. "KCDC COVID-19 situation reports in South Korea (01 Mar 2020)"[URL]
26. "WHO Summary of probable SARS cases with onseto fillness from 1 November 2002 to 31 July 2003"[URL]
27. "WHO Middle East respiratory syndrome coronavirus (MERS-CoV) monthly summary" (2019)[URL]
28. Pan X, "Asymptomatic cases in a family cluster with SARS-CoV-2infection", Lancet Infect. Dis. (2020)
29. Yan Bai, "Presumed Asymptomatic Carrier Transmission of COVID-19", JAMA, 323(14), pp.1406~ (2020), American Medical Association (AMA)[DOI]
30. Rothe C, "Transmission of 2 019-nCoV infection from an asymptomatic contact in Germany", N. Engl. J. Med., 382, pp.970~971 (2020)
31. Chen Y, "A sensitive and specific antigen detection assay for Middle East respiratory syndrome coronavirus", Emerg. Microbes Infect, 4, pp.e26~ (2015)
32. Meyer B, "Serological assays for emerging coronaviruses : challenges and pitfalls", Virus Res, 194, pp.175~183 (2014)
33. Zhu N, "A Novel Coronavirus from patients with pneumonia in China, 2019", N. Engl. J. Med, 382, pp.727~733 (2020)
34. Wang C, "A novel coronavirus outbreak of global health concern", Lancet, 395, pp.470~473 (2020)
35. Corman VM, "Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR", Euro Surveill., 25(3) (2020)[DOI]
36. "WHO Coronavirus disease (COVID-19) technical guidance:Laboratory testing for 2019-nCoV in humans"[URL]
37. Wang Y, "Cross talk between nucleotide synthesis pathways with cellular immunity in constraining hepatitis E virus replication", Antimicrob. Agents Chemother, 60, pp.2834~2848 (2016)
38. Debing Y, "Ribavirin inhibits in vitro hepatitis E virus replication through depletion of cellular GTP pools and is moderately synergistic with alpha interferon", Antimicrob. Agents Chemother, 58, pp.267~273 (2014)
39. Leyssen P, "The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase", J. Virol, 79, pp.1943~1947 (2005)
40. De Clercq E, "New nucleoside analogues for the treatment of hemorrhagic fever virus infections", Chem. Asian J, 14, pp.3962~3968 (2019)
41. Wang M, "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus(2019-nCoV)in vitro", Cell Res, 30, pp.269~271 (2020)
42. So LK, "Development of a standard treatment protocol for severe acute respiratory syndrome", Lancet, 361, pp.1615~1617 (2003)
43. Al-Tawfiq JA, "Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus : an observational study", Int. J. Infect. Dis, 20, pp.42~46 (2014)
44. Zumla A, "Coronaviruses-drug discovery and therapeutic options", Nat. Rev. Drug Discov, 15, pp.327~347 (2016)
45. Choy M, "Pharmaceutical approval update", PT, 41, pp.416~441 (2016)
46. Sheahan TP, "Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses", Sci. Transl. Med., 9 (2017)
47. Mulangu S, "A Randomized, controlled trial of ebola virus disease therapeutics", N. Engl. J. Med, 381, pp.2293~2303 (2019)
48. Holshue ML, "First Case of 2019 Novel Coronavirus in the United States", N. Engl. J. Med, 382, pp.929~936 (2020)
49. Yan Y, "Antimalaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model", Cell Res, 23, pp.300~302 (2013)
50. Savarino A, "New insights into the antiviral effects of chloroquine", Lancet Infect. Dis, 6, pp.67~69 (2006)
51. Kono M, "Inhibition of human coronavirus 229E infection in human epithelial lung cells(L132)by chloroquine : involvement of p38 MAPK and ERK", Antiviral Res, 77, pp.150~152 (2008)
52. Vincent MJ, "Chloroquine is a potent inhibitor of SARS coronavirus infection and spread", Virol. J, 2, pp.69~ (2005)
53. Keyaerts E, "In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine", Biochem. Biophys. Res. Commun, 323, pp.264~268 (2004)
54. Savarino A, "Effects of chloroquine on viral infections: an old drug against today’s diseases?", Lancet Infect. Dis., 3, pp.722~727 (2003)
55. Gao J, "Breakthrough : Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies", Biosci. Trends, 14, pp.72~73 (2020)
56. Wu CY, "Small molecules targeting severe acute respiratory syndrome human coronavirus", Proc. Natl. Acad. Sci. USA, 101, pp.10012~10017 (2004)
57. Mukherjee P, "Structure-based virtual screening against SARS-3CL(pro)to identify novel non-peptidic hits", Bioorg. Med. Chem, 16, pp.4138~4149 (2008)
58. Chu CM, "Role of lopinavir", ritonavir in the treatment of SARS : initial virological and clinical findings, 2004, pp.59, 252~256
59. Chan KS, "Treatment of severe acute respiratory syndrome with lopinavir", ritonavir : a multicentre retrospective matched cohort study, 2003, pp.9, 399~406
60. "MSIT Research projects initiation for drug repositioning study for COVID-19 treatment"[URL]
61. Zhang C, "Advances in mRNA vaccines for infectious diseases", Front Immunol, 10, pp.594~ (2019)
62. Andre FE., "The future of vaccines, immunisation concepts and practice", Vaccine, 19, pp.2206~2209 (2001)
63. Pronker ES, "Risk in vaccine research and development quantified", PLoS One, 8, pp.e57755~ (2013)
64. Guarner J, "Three emerging coronaviruses in two decades", Am. J. Clin. Pathol, 153, pp.420~421 (2020)
65. Du L, "The spike protein of SARS-CoV--a target for vaccine and therapeutic development", Nat. Rev. Microbiol, 7, pp.226~236 (2009)
66. Coutard B, "The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade", Antiviral Res, 176, pp.104742~ (2020)
67. Li F, "Structure, function, and evolution of coronavirus spike proteins", Annu. Rev. Virol, 3, pp.237~261 (2016)
68. Sun C, "SARS-CoV-2 and SARS-CoV Spike-RBD structure and receptor binding comparison and potential implications on neutralizing antibody and vaccine development", BioRxiv (2020)[DOI]
69. He Y, "Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies : implication for developing subunit vaccine", Biochem. Biophys. Res. Commun, 324, pp.773~781 (2004)
70. Okba NM, "Middle East respiratory syndrome coronavirus vaccines : current status and novel approaches", Curr. Opin. Virol, 23, pp.49~58 (2017)
71. Bisht H, "Neutralizing antibody and protective immunity to SARS coronavirus infection of mice induced by a soluble recombinant polypeptide containing an N-terminal segment of the spike glycoprotein", Virology, 334, pp.160~165 (2005)
72. "Clover Biopharmaceuticals vaccines programs"[URL]
73. "CEPI and GSK announce collaboration to strengthen the global effort to develop a vaccine for the 2019-nCoV virus"[URL]
74. "‘Significant step’ in COVID-19 vaccine quest"[URL]
75. "CEPI to fund three progrannes to develop vaccines against the novel coronavirus (nCoV-2019)"[URL]
76. Yang ZY, "A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice", Nature, 428, pp.561~564 (2004)
77. Sardesai NY, "Electroporation delivery of DNA vaccines : prospects for success", Curr. Opin. Immunol, 23, pp.421~429 (2011)
78. "Inovio Accelerates Timeline for COVID-19 DNA Vaccine INO-4800"[URL]
79. "Inovio’s produc pipeline"[URL]
80. "dMAb Technology platform"[URL]
81. Pardi N, "mRNA vaccines-a new era in vaccinology", Nat. Rev. Drug Discov, 17, pp.261~279 (2018)
82. "Moderna’s pipeline"[URL]
83. "mRNA platform: Enabling Drug Discovery & Development"[URL]
84. "hyFc platform"[URL]
85. Seo YB, "Crucial roles of interleukin-7 in the development of T follicular helper cells and in the induction of humoral immunity", J. Virol, 88, pp.8998~9009 (2014)
86. Lee JH, "The pharmacology study of a new recombinant TNF receptor-hyFc fusion protein", Biologicals, 41, pp.77~83 (2013)
87. Loset GA, "Differential segmental flexibility and reach dictate the antigen binding mode of chimeric IgD and IgM : implications for the function of the B cell receptor", J. Immunol, 172, pp.2925~2934 (2004)
88. 강문철, "Plasmacytoid Dendritic Cells Contribute to the Protective Immunity Induced by Intranasal Treatment with Fc-fused Interleukin-7 against Lethal Influenza Virus Infection", Immune Network, 17(5), pp.343~351 (2017), 대한면역학회[DOI]
89. Tirado SM, "Antibody-dependent enhancement of virus infection and disease", Viral Immunol, 16, pp.69~86 (2003)
90. Khandia R, "Modulation of Dengue", Zika Virus pathogenicity by antibody-dependent enhancement and strategies to protect against enhancement in Zika Virus infection, 2018, pp.9, 597~
91. Wan Y, "Molecular mechanism for antibody-dependent enhancement of coronavirus entry", J. Virol., 94(5), pp.e02015~e02019 (2020)
92. Wang SF, "Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins", Biochem. Biophys. Res. Commun, 451, pp.208~214 (2014)
93. Kim TW, "Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus", J. Virol, 78, pp.4638~4645 (2004)
94. Duffy S., "Why are RNA virus mutation rates so damn high?", PLoS Biol., 16, pp.e3000003~ (2018)
95. Zhou P, "A pneumonia outbreak as sociated with a new coronavirus of probable bat origin", Nature, 579, pp.270~273 (2020)
96. Yeager CL, "Human aminopeptidase N is a receptor for human coronavirus 229E", Nature, 357, pp.420~422 (1992)
97. Hofmann H, "Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry", Proc. Natl. Acad. Sci. USA, 102, pp.7988~7993 (2005)
98. Tresnan DB, "Feline aminopeptidase N serves as a receptor for feline, canine, porcine, and human coronaviruses in serogroup I", J. Virol, 70, pp.8669~8674 (1996)
99. Delmas B, "Aminopeptidase N is a major receptor for the entero-pathogenic coronavirus TGEV", Nature, 357, pp.417~420 (1992)
100. Li W, "Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus", Nature, 426, pp.450~454 (2003)
101. Raj VS, "Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC", Nature, 495, pp.251~254 (2013)
102. Krempl C, "Analysis of cellular receptors for human coronavirus OC43", Adv. Exp. Med. Biol, 380, pp.371~374 (1995)
103. Huang X, "Human coronavirus HKU1 spike protein uses Oacetylated sialic acid as an attachment receptor determinant and employs hemagglutinin-esterase protein as a receptor-destroying enzyme", J. Virol, 89, pp.7202~7213 (2015)
104. Williams RK, "Receptor for mouse hepatitis virus is a member of the carcinoembryonic antigen family of glycoproteins", Proc. Natl. Acad. Sci. USA, 88, pp.5533~5536 (1991)

관련 논문AI추천